Correction: AB Klaipėdos nafta preliminary revenue for the August 2020
Correction: Announcing preliminary revenue for August 2020 the mistake was made in the text referring to preliminary sales revenue of oil terminals for the first eight months of 2020, as well as incorrectly indicated reporting month in Lithuanian language announcement in the management comment section. Updated information presented in bold below:
AB Klaipėdos nafta (further the Company) reviewed operating segments since the beginning of the second quarter of 2020 and presents revenue disclosures accordingly. The following operating segments of the Company are:
- Oil terminals activity, that includes Klaipėda oil terminal and Subačius oil terminal,
- Regulated LNG activity in Klaipėda and
- Commercial LNG activity, that includes small-scale LNG reloading station in Klaipėda and Business development projects.
The preliminary sales revenue of the Company’s oil terminals for the August 2020 comprised EUR 2.6 million and is lower by EUR 0.4 million or by 13.3 % compared to August of 2019. The preliminary sales revenue is lower due to decrease of transhipment quantities of oil products, compared to the same period of 2019. The preliminary sales revenue of the Company’s oil terminals for the first eight months of 2020 comprised EUR 21.1 million and is in the same level as compared to the same period of 2019.
The preliminary sales revenue of the Company LNG terminal for August 2020 comprised EUR 3.4 million (during the same month of 2019 – EUR 5.8 million). LNG terminal revenue consists of the regasification tariff fixed part (for booked annual capacities), variable part for amount of re-gasified LNG and reloading revenue from regulated activities. The level of Klaipėda LNG terminal revenue (for booked annual capacities) does not depend on regasification volume. Revenue is confirmed by the National Energy Regulatory Council (NERC) based on the approved methodology of State regulated prices in the natural gas sector and is calculated for the whole upcoming year. The preliminary sales revenue of LNG terminal for the first eight months of 2020 decreased by 38.5 % due to the reduction of security supplement of Klaipėda LNG terminal from the 1st January of 2020.
The preliminary sales revenue of the Company’s Commercial LNG activity for the August 2020 comprised EUR 0.2 million. If compared to the respective period last year, the preliminary sales revenue is higher due to Business development projects consultation revenue and increase of small-scale LNG station revenue. The preliminary sales revenue of the Company’s Commercial LNG activity for the first eight months of 2020 comprised EUR 1.8 million.
Total preliminary sales revenue of the Company for the January-August 2020 amount to EUR 52.0 million and is lower by 24.5 % compared to the same period of 2019 - EUR 68.9 million.
Preliminary revenue of the Company, EUR million:
|August||January - August|
|Oil terminals activity||2.6||3.0||-13.3%||21.1||21.5||-1.9%|
|LNG terminal activity||3.4||5.8||-41.4%||29.1||47.3||-38.5%|
|Commercial LNG activity||0.2||0.0||100.0%||1.8||0.1||17 times|
Comment by the Company management
In August there still has been a lot of uncertainty, which has been influenced by COVID-19 impact on the economies, which also affects results of KN. Our clients seek to preserve their profitability, wherefore the demand for the oil products storage has increased, however, it negatively influenced transhipment quantities of oil products. Despite the unfavourable circumstances, KN managed to secure same preliminary sales revenue of the Company’s oil terminals for the eight months of 2020 compared to the same period of 2019. Furthermore, we expect that our long-term partners in Belarus will meet their annual commitments to tranship agreed quantities of petroleum products and political activity will not be affect the dialogue on cooperation for the next contractual period.
The main factor, which influenced the total Company‘s revenue result in January-August, 2020, was lower revenue of Klaipėda LNG terminal, following from the KN decisions, adopted in 2019, to optimize Klaipėda LNG terminal costs and reduce the cost of LNG terminal infrastructure for consumers, starting from 2020.
Jonas Lenkšas, Chief Financial Officer, +370 694 80594
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
EPH European Property Holdings Limited (EPH) announces plans to issue and offer up to 4,500,000 new ordinary shares23.11.2020 19:00:00 CET | Press release
23 November 2020, Road Town, Tortola, BVI EPH European Property Holdings Ltd (the "Company"), an investment company listed on SIX Swiss Exchange which holds an extensive property portfolio with a total value of around USD 1.3 billion across Europe, announces its intention to issue and offer up to 4,500,000 new ordinary shares for a consideration equaling the last reported net asset value (as per 30 June 2020) in the amount of USD 38.82 per share (the "Offer Shares"). EPH will hold a virtual conference on Monday, 30 November 2020 at 3 pm CET to explain details of the capital increase and the company's strategy. You are welcome to register for this event. Please contact firstname.lastname@example.org receive dial-in data. The proceeds from the issue of the Offer Shares will be used for funding our future growth through, including, without limitation, the following: acquisition of additional income generating or to be developed commercial properties and investments in our existing real es
Idorsia announces positive results of the two Japanese registration studies with clazosentan23.11.2020 17:45:10 CET | Press release
Clazosentan demonstrates significant reduction of vasospasm-related morbidity and all-cause mortality in patients following aneurysmal subarachnoid hemorrhage (aSAH)Clazosentan demonstrates significant reduction of all-cause morbidity and mortality in patients following aSAH in a pre-planned pooled analysis of data from both studies.Idorsia Japan to file New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021Global Phase 3 study “REACT” investigating the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in adult patients following aSAH continues to actively recruit Allschwil, Switzerland – November 23, 2020 Idorsia Ltd (SIX: IDIA) today announced positive top-line results of the Japanese registration program investigating clazosentan in adult Japanese patients post-aSAH. The program consisted of two double-blind, randomized, placebo-controlle
Saniona rapporterar positiva topline-resultat från den öppna förlängningen av Fas 2-studien med Tesomet mot hypotalamisk fetma23.11.2020 17:00:00 CET | Pressemelding
PRESSMEDDELANDE 23 november 2020 Tesomet tolererades väl av patienterna med hypotalamisk fetma under hela den 48 veckor långa studien (24 veckor dubbelblind del följt av 24 veckor öppen förlängning). Inga kliniskt betydelsefulla skillnader kunde noteras avseende hjärtfrekvens eller blodtryck och samtliga patienter som påbörjade den öppna förlängningsstudien slutförde också studien.De patienter som fick Tesomet under hela den 48 veckor långa studietiden påvisades statistiskt signifikanta och kliniskt meningsfulla minskningar av kroppsvikt och midjeomfång från baseline till vecka 48, liksom förbättrad glykemisk kontroll. De förbättringar som observerades under den första dubbelblinda delen av studien bibehölls under hela den senare öppna förlängningsstudien. Även för de patienter som fick placebo under den dubbelblinda delen av studien och sedan Tesomet under den öppna förlängningsstudien påvisades minskningar av kroppsvikt och midjeomfång efter övergången till Tesomet.Saniona kommer att
Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity23.11.2020 17:00:00 CET | Press release
PRESS RELEASE November 23, 2020 Tesomet was well-tolerated in hypothalamic obesity patients throughout the duration of the 48-week trial (24 week double-blind [DB] followed by 24 week open label extension [OLE]), with no clinically meaningful differences in heart rate or blood pressure observed. All patients who entered the OLE study completed it.Patients receiving Tesomet for the full 48 weeks of the study demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference from baseline to Week 48, as well as improvements in glycemic control. Improvements observed in the DB period of the study were maintained over the duration of the OLE period. Patients who received placebo in the DB period of the study and were subsequently switched to Tesomet for the OLE period also achieved reductions in body weight and waist circumference after being switched to Tesomet.Saniona to host webcast with Dr. Ulla Feldt-Rasmussen on Tuesday, 24 November 202
Incap Corporation: Notification in accordance with chapter 9, section 10 of the securities market act on a change in holdings (Oy Etra Invest Ab)23.11.2020 16:30:00 CET | Press release
Incap Corporation Stock Exchange Release 23 November 2020 at 5.30 p.m. (EET) Notification in accordance with Chapter 9, Section 10 of the Securities Market Act on a Change in Holdings (Oy Etra Invest Ab) Incap Corporation has on 23 November 2020 received a notification in accordance with the Securities Market Act, according to which the total holdings of shares and votes of Erkki Etola and the entities controlled by him (Tiiviste-Group Oy and Oy Etra Invest Ab) in Incap Corporation (FI0009006407) has increased over 20 percent threshold. Shareholder: Erkki Etola and entities controlled by him Position of previous notification: 19.20 % out of all shares and votes Date of change in holdings: 20 November 2020 Resulting situation on the date on which threshold was crossed: 1,327,333 shares, i.e. 22.81 % out of all shares and votes Incap Corporation's total number of shares amounts to 5,820,224 and each share has one vote. After November 20, 2020, Erkki Etola's direct holding of shares and v
USD TENDER OPERATION ANNOUNCEMENT23.11.2020 16:20:00 CET | Press release
Bid date, 2020-11-25Bid Date2020-11-25Bid times14.00-14.30 (CET/CEST) on the Bid dateOfferent AmountUSD 10 billionMaximum Permitted Volume of BidsUSD 4 billion from an individual institutionSettlement Date2020-11-30Minimum Permitted Bid Volume100 USD million per bidMaximum Allocation40 per cent of the Offerend amountAllocation timeNo later than 15.00 (CET/CEST) on the Bid dateMaturity Date2021-02-22Maximum Number of Bids10 per individual institutionLowest Interest Supplement0,25 percentage pointsConfirmation of bids to email@example.com Stockholm, 2020-11-23 This is a translation of the special terms and conditions published on riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail.